SCHEMBL5231287

SCHEMBL5231287

CCOc1ccc2c(CC(=O)c3ccccn3)ccnc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
PKM P14618 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MITF O75030 2/20 0.49
MAPT P10636 7/20 0.47
KMT2A Q03164 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
OPRK1 P41145 1/20 0.47
PAX8 Q06710 1/20 0.44
GRM4 Q14833 3/20 0.43
LMNA P02545 4/20 0.42
MEN1 O00255 2/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 2/20 0.42
AXL P30530 1/20 0.41
ACACB O00763 1/20 0.41
PTGER1 P34995 1/20 0.41
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232920 0.89 RAB9A (0.49) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL5238328 0.85 THRB (0.44) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL5236574 0.80 TSHR (0.48) SMN1; SMN2PKMKDM4EKMT2AGRM4
SCHEMBL5231726 0.80 GRM4 (0.44) NPC1RAB9ASMN1; SMN2KDM4EKMT2A
SCHEMBL4872056 0.79 CYP1A2 (0.55) KDM4EKMT2AGRM4LMNAHTT
SCHEMBL4873486 0.77 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL5235795 0.74 KDR (0.45) NPC1RAB9ALMNAALDH1A1
SCHEMBL5233499 0.74 GRM4 (0.43) NPC1SMN1; SMN2KDM4EMAPTKMT2A
SCHEMBL6703618 0.73 RAB9A (0.51) NPC1RAB9ASMN1; SMN2PKMKDM4E
SCHEMBL5923675 0.72 FERMT2 (0.46) NPC1RAB9ASMN1; SMN2PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 EP disclosed
WO-2004026302-A1 METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES ELI LILLY AND COMPANY (US) 2004-04-01 WO disclosed